Pharmalittle: House to grill pharma wholesalers over opioids; Novartis tries a gambit to promote biosimilars

first_img By Ed Silverman May 7, 2018 Reprints About the Author Reprints Daily reporting and analysis The most comprehensive industry coverage from a powerhouse team of reporters Subscriber-only newsletters Daily newsletters to brief you on the most important industry news of the day STAT+ Conversations Weekly opportunities to engage with our reporters and leading industry experts in live video conversations Exclusive industry events Premium access to subscriber-only networking events around the country The best reporters in the industry The most trusted and well-connected newsroom in the health care industry And much more Exclusive interviews with industry leaders, profiles, and premium tools, like our CRISPR Trackr. Alex Hogan/STAT Pharmalot Columnist, Senior Writer Ed covers the pharmaceutical industry. Unlock this article — plus daily coverage and analysis of the pharma industry — by subscribing to STAT+. First 30 days free. GET STARTED What’s included? STAT+ is STAT’s premium subscription service for in-depth biotech, pharma, policy, and life science coverage and analysis. Our award-winning team covers news on Wall Street, policy developments in Washington, early science breakthroughs and clinical trial results, and health care disruption in Silicon Valley and beyond. Pharmalittle: House to grill pharma wholesalers over opioids; Novartis tries a gambit to promote biosimilars Good morning, everyone, and welcome to another working week. We hope the weekend respite was relaxing and refreshing because, once again, that predictable routine of meetings, deadlines, and the like has returned. After all, the world keeps spinning. And to cope, yes, we are relying on cups of stimulation to help us along. Feel free to join us. Remember, no prescription is required. Meanwhile, here are some tidbits to get you going. Hope your day is simply smashing and do keep in touch. We enjoy your notes and dossiers …Gabapentin, a 25-year-old generic pill long seen as a low-risk way to treat seizures, nerve pain, and other ailments, is the latest drug raising red flags that is not part of the opioid family at the center of the nation’s drug epidemic, the Associated Press writess. It is one of the most prescribed medications in the U.S., ranking ninth over the last year, according to prescription tracker GoodRx. Researchers attribute the recent surge to tighter restrictions on opioid painkillers, which have left doctors searching for alternatives for their patients.center_img Log In | Learn More GET STARTED @Pharmalot Ed Silverman Tags drug pricinglegalopioidspharmaceuticalspharmalittleSTAT+Vaccines Pharmalot [email protected] What is it?last_img

Leave a Reply

Your email address will not be published. Required fields are marked *